Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in refractory rheumatoid arthritis
NCT07008196Phase 4Not yet recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of telitacicept in rheumatoid arthritis (RA), sponsored by Chinese SLE Treatment And Research Group. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07008196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008196.